Life Star1

Accelerating drug discovery with robotic automation and generative AI.

by Insilico Medicine · Lab Management & ELN

Executive Summary

Life Star1 is a cutting-edge, fully robotic laboratory designed to revolutionize pharmaceutical research and development. It provides a highly automated environment for conducting complex experiments, optimizing research workflows, and generating high-quality data with unparalleled efficiency and reproducibility. This robotic system minimizes manual intervention, reduces human error, and significantly accelerates the pace of scientific discovery. Seamlessly integrated with Insilico Medicine's Pharma.AI platform, Life Star1 leverages advanced generative artificial intelligence to enhance every stage of the drug discovery pipeline. The AI platform, encompassing tools like PandaOmics for target discovery and Chemistry42 for small molecule design, guides experimental design, interprets results, and provides intelligent recommendations. This synergy between robotic automation and AI-driven insights enables rapid validation of hypotheses and the swift progression of novel drug candidates. By bridging the gap between computational design and physical experimentation, Life Star1 empowers researchers to move from initial concepts to clinical trials faster and more cost-effectively. It embodies Insilico Medicine's mission to extend healthy, productive longevity by transforming drug discovery and development through an end-to-end AI and automation platform.

Use Cases

  • Automated high-throughput screening of compounds.
  • Rapid validation of AI-generated drug candidates and hypotheses.
  • Optimization of experimental protocols and conditions.
  • Accelerated lead identification and optimization in drug discovery.
  • Reproducible data generation for preclinical research.

Features

Visibility

  • Real-time Experiment Monitoring: Track the progress of automated experiments and robotic operations in real-time.
  • Data Visualization: Visualize experimental results, analytical insights, and key performance indicators through interactive dashboards.
  • Workflow Management Interface: Manage and schedule experimental workflows, protocols, and resource allocation.

Intelligence

  • AI-Driven Hypothesis Generation: Leverage generative AI to propose novel drug targets, molecular structures, and experimental designs.
  • Automated Data Interpretation: Receive AI-powered analysis and interpretation of complex experimental data to accelerate decision-making.
  • Predictive Modeling: Utilize machine learning models to predict experimental outcomes and optimize research strategies.

Technical Specifications

Architecture
A hybrid architecture combining on-premise robotic laboratory hardware with a cloud-based generative AI software platform (Pharma.AI) for seamless data exchange and intelligent control.
Deployment
Hybrid
API Available
Yes

AI/ML Stack

  • Generative AI
  • Machine Learning
  • Deep Learning
  • PandaOmics
  • Chemistry42
  • Generative Biologics

Integrations

  • Pharma.AI
  • PandaOmics
  • Chemistry42
  • Generative Biologics
  • Science42:DORA

Pricing

Starting Price
Contact sales
Target Customer
Enterprise,Mid-Market

About Insilico Medicine

Insilico Medicine is a clinical-stage biotechnology company that leverages artificial intelligence and deep learning to accelerate drug discovery and development. The company focuses on therapeutic solutions for cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions, utilizing its proprietary Pharma.AI platform to discover novel targets, design new molecules, and advance candidates into human clinical trials.

Founded: 2014 · Headquarters: Boston, Massachusetts, United States · Employees: 201-500 · Public